Parataxis Holdings, a global investment firm focused on blockchain and digital assets, has acquired South Korea-based Bridge Biotherapeutics for $18.5 million. The acquisition marks a strategic pivot for the biotech firm, which will now operate under the name Parataxis Korea and shift its focus to launching an institutionally backed Bitcoin treasury platform, inspired by the models of MicroStrategy and Metaplanet.
The move shows Parataxis Holdings’ ambition to establish a foothold in Asia’s growing digital asset market. Parataxis Korea aims to enable institutional investors and corporations to adopt Bitcoin as a treasury reserve asset, following the blueprint of MicroStrategy’s billion-dollar Bitcoin strategy and Metaplanet’s innovative crypto treasury approach. The platform will offer secure custody solutions, advanced analytics, and compliance tools tailored to South Korea’s regulatory landscape.
“South Korea is a hub for technological innovation and financial adoption,” said Edward Wilson, CEO of Parataxis Holdings. “By transforming Bridge Biotherapeutics into Parataxis Korea, we’re combining our expertise in digital assets with a trusted local brand to deliver a robust Bitcoin treasury platform for institutional clients.”
Bridge Biotherapeutics, previously focused on developing treatments for inflammatory and fibrotic diseases, will cease its biotech operations as part of the rebranding. The acquisition includes Bridge’s existing infrastructure and talent pool, which will be repurposed to support Parataxis Korea’s blockchain initiatives.
The announcement has sparked interest in South Korea’s crypto community, with analysts noting the potential for Parataxis Korea to drive mainstream corporate adoption of Bitcoin in the region. The platform is expected to launch in Q4 2025, with partnerships already in discussion with leading financial institutions.
